Replies to post #1580 on Conatus Pharmaceuticals Inc. (CNAT)

[Theo]

Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

[drugmanrx]

Actually was referring to the "public offering", mis-name it sorry.

What private placement?

https://globenewswire.com/news-release/2017/05/10/982052/0/en/Conatus-Announces-Proposed-Public-Offering-of-Common-Stock.html

SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Conatus also expects to grant to the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Conatus. Conatus intends to use the net proceeds from the offering to fund pipeline expansion, to repurchase and retire 2,166,836 shares of its common stock held by funds affiliated with Advent Private Equity at a price equal to the net proceeds per share that Conatus will receive from this offering, before expenses, and for working capital and other general corporate purposes.

Stifel and SunTrust Robinson Humphrey are acting as book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The securities described above are being offered by Conatus pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at [phone] or by email at [e-mail], or by contacting SunTrust Robinson Humphrey by mail at 3333 Peachtree Road NE, Atlanta, GA 30326, Attention: Prospectus Department, by telephone at [phone] or by email at [e-mail]. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at www.sec.gov.